Granted Patent
B2
US 12,643,870 · App. 18/747,813 · Granted Jun 2, 2026
1,2,4-oxadiazole derivatives as immunomodulators
Inventors:
Pottayil Govindan Nair Sasikumar (Bangalore, IN); Muralidhara Ramachandra (Bangalore, IN); Seetharamaiah Setty Sudarshan Naremaddepalli (Bangalore, IN)
Assignee:
Aurigene Oncology Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R 1 is the side chain of Ser, R 2 is —CO-Thr, R 3 is the side chain of Asn or Glu, and R 4 , R 5 and R 6 are each H.
Claims (26)
1 . A pharmaceutically acceptable salt of a compound selected from the group consisting of:
2 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
3 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
4 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
5 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
6 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
7 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
8 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
9 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
10 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
11 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
12 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
13 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
14 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
15 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
16 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
17 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
18 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
19 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
20 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
21 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
22 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
23 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
24 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
25 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
26 . The pharmaceutically acceptable salt of claim 1 , wherein the compound is
Priority Claims (1)
IN 4011/CHE/2013
· Sep 6, 2013
· national
Continuity (8)
References Cited (197)
US 3227725A
· Fernand et al.
· 1966
[cited by applicant]
US 5387585A
· Borer et al.
· 1995
[cited by applicant]
US 5665718A
· Godel et al.
· 1997
[cited by applicant]
US 8735553B1
· Li et al.
· 2014
[cited by applicant]
US 9771338B2
· Sasikumar et al.
· 2017
[cited by applicant]
US 20070197522A1
· Edwards et al.
· 2007
[cited by applicant]
US 20110275673A1
· Xiang et al.
· 2011
[cited by applicant]
US 20130022629A1
· Sharpe et al.
· 2013
[cited by applicant]
US 20150073024A1
· Sasikumar et al.
· 2015
[cited by applicant]
US 20200061030A1
· Sasikumar et al.
· 2020
[cited by applicant]
US 20230062570A1
· Sasikumar et al.
· 2023
[cited by applicant]
US 20230110077A1
· Sasikumar et al.
· 2023
[cited by applicant]
US 20250136562A1
· Sasikumar et al.
· 2025
[cited by applicant]
US 20250144082A1
· Sasikumar et al.
· 2025
[cited by applicant]
US 20250188045A1
· Yu
· 2025
[cited by applicant]
US 20250195478A1
· Sasikumar et al.
· 2025
[cited by applicant]
CN 105814028A
· 2016
[cited by applicant]
CN 111163772A
· 2020
[cited by applicant]
JP 2014180462A
· 2014
[cited by applicant]
JP 2016532710A
· 2016
[cited by applicant]
JP 2021501127A
· 2021
[cited by applicant]
KR 20160081897A
· 2016
[cited by applicant]
WO 2001014557A1
· 2001
[cited by applicant]
WO 2002079499A1
· 2002
[cited by applicant]
WO 2002086083A2
· 2002
[cited by applicant]
WO 2003042402A2
· 2003
[cited by applicant]
WO 2003070711A1
· 2003
[cited by applicant]
WO 2004004771A1
· 2004
[cited by applicant]
WO 2004056875A1
· 2004
[cited by applicant]
WO 2005056550A2
· 2005
[cited by applicant]
WO 2006121168A1
· 2006
[cited by applicant]
WO 2006133216A2
· 2006
[cited by applicant]
WO 2007075749A2
· 2007
[cited by applicant]
WO 2008011557A2
· 2008
[cited by applicant]
WO 2008039431A2
· 2008
[cited by applicant]
WO 2008156712A1
· 2008
[cited by applicant]
WO 2009006555A2
· 2009
[cited by applicant]
WO 2009059162A1
· 2009
[cited by applicant]
WO 2009105712A1
· 2009
[cited by applicant]
WO 2010051447A1
· 2010
[cited by applicant]
WO 2010077634A1
· 2010
[cited by applicant]
WO 2011066389A1
· 2011
[cited by applicant]
WO 2011082400A2
· 2011
[cited by applicant]
WO 2011137587A1
· 2011
[cited by applicant]
WO 2011161699A2
· 2011
[cited by applicant]
WO 2012129564A2
· 2012
[cited by applicant]
WO 2012168944A1
· 2012
[cited by applicant]
WO 2013132317A1
· 2013
[cited by applicant]
WO 2013144704A1
· 2013
[cited by applicant]
WO 2014055897A2
· 2014
[cited by applicant]
WO 2014059173A2
· 2014
[cited by applicant]
WO 2014100079A1
· 2014
[cited by applicant]
WO 2014110298A1
· 2014
[cited by applicant]
WO 2014141104A1
· 2014
[cited by applicant]
WO 2014147586A1
· 2014
[cited by applicant]
WO 201503299A1
· 2015
[cited by applicant]
WO 2015033301A1
· 2015
[cited by applicant]
WO 2016073470A1
· 2016
[cited by applicant]
WO 2016142833A1
· 2016
[cited by applicant]
WO 2016142852A1
· 2016
[cited by applicant]
WO 2016142886A2
· 2016
[cited by applicant]
WO 2017055860A1
· 2017
[cited by applicant]
WO 2017079116A2
· 2017
[cited by applicant]
WO 2018047143A1
· 2018
[cited by applicant]
WO 2018051254A1
· 2018
[cited by applicant]
WO 2018073754A1
· 2018
[cited by applicant]
WO 2019061324A1
· 2019
[cited by applicant]
WO 2019067678A1
· 2019
[cited by applicant]
WO 2019087087A1
· 2019
[cited by applicant]
WO 2019087092A1
· 2019
[cited by applicant]
Liu et al., Small-Molecule Radiotracers for Visualization of V-Domain Immunoglobulin Suppressor of T Cell Activation, Journal of Medicinal Chemistry, 67:17690-17700, 2024.
[cited by applicant]
Takada, API form screening and selection in drug discovery stage, Pharm Stage, 6(10):20-25, 2007.
[cited by applicant]
Alsaab et al., “PD-1 and PD-L1 Checkpoint Signaling Inhibition for CancerImmunotherapy: Mechanism, Combinations, and Clinical Outcome” Frontiers in Pharmacology, 8(561) (2017).
[cited by applicant]
Ansell, Stephen M. “PD-1 Is Expressed on B-Cells in Waldenstrom Macroglobulinemia and Promotes Malignant Cell Viability and Proliferation” Blood, 124(21) (2014).
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates “the 100 mg-approach”.” International Journal of Pharmaceutics 275(1-2):1-12 (2004).
[cited by applicant]
Baldoni et al., “A New Reversible and Potent P2Y 12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial”, Clinical Drug Investigation, Nov. 1, 2014.
[cited by applicant]
Caira, “Crystalline polymorphism of organic compounds.” Design of Organic Solids (1998): 163-208.
[cited by applicant]
Cedres et al., “Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)” Plos One DOI:10.1371 (2015).
[cited by applicant]
Curiel et al., “Blockade of B7-H1 improves myeloid dendritic cell-mediated anitumor immunity” Nature Medicine, 9 (5) (2003).
[cited by applicant]
Extended European Search Report for EP Application No. 21209727.3 mailed May 18, 2022.
[cited by applicant]
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science, 286(5439): 531-537 (1999).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/053052 dated Jan. 29, 2019 .
[cited by applicant]
Jin, “Role of PD-1 in Regulating T-Cell Immunity,” Current Topics in Microbiology and Immunology, 350: 17-37 (2010).
[cited by applicant]
Lala et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors”, Cancer and Metastasis Reviews 17:91-106 (1998).
[cited by applicant]
Lazorchak et al., “Abstract A36: CA-170, an oral small molecule PD-L1 and VISTA immune checkpoint antagonist, promotes T cell immune activation and inhibits tumor growth in pre-clinical models of cancer,” Cancer Immunol…
[cited by applicant]
Lemercier et al., “VISTA regulates the development of protective antitumor immunity.” Cancer Research 74 (7):1933-1944 (2014).
[cited by applicant]
Liu et al., “Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses,” PNAS, 112(21): 6682-6687 (2015).
[cited by applicant]
Luo et al., “Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction,” Cell, 136(5): 823-837 (2009).
[cited by applicant]
Marechal et al., “1,2,4-oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome,” Curr Med Chem 20(18):2351-2362 (2013).
[cited by applicant]
Melero et al., “Evolving Synergistic Combinations of Targeted Immunotherapies to Combat Cancer”, Nature Reviews Cancer 15:457-472 (2015).
[cited by applicant]
Moussebois et al., “Synthese de Deux Nouveaux Acides Amines Phenoliques Comportant un Cycle 1,2,4-Oxadiazole,” Helv. Chim. ACTA, 60(1):237-242 (1977).
[cited by applicant]
Singhal et al., “Drug polymorphism and dosage form design: a practical perspective.” Advanced Drug Delivery Reviews 56(3):335-347 (2004).
[cited by applicant]
Swaika et al., “Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy” Molecular Immunology (2015).
[cited by applicant]
Lazorchak et al., “P279: An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Journal for Imm…
[cited by applicant]
Lazorchak et al., “An oral small molecule combination therapy targeting PD-L1, VISTA and Tim-3 immune inhibitory checkpoints exhibits enhanced anti-tumor efficacy in pre-clinical models of cancer,” Published by Curis, N…
[cited by applicant]
National Institutes of Health, “Cancer” Medline Plus, medlineplus.gov/cancer.html, retrieved on Jun. 30, 2023.
[cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Cancer Research 76.14 (Jul. 31, 2016).
[cited by applicant]
Sasikumar et al., “Oral immune checkpoint antagonists targeting PD-L1/VISTA and PD-L1/Tim3 for cancer therapy,” Published by Curis, Oct. 1, 2019.
[cited by applicant]
Anderson et al., “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation,” Immunity, 44(5): 989-1004 (2016).
[cited by applicant]
Ardestani et al., “Cell death features induced in Leishmania major by 1,3,4-thiadiazole derivatives,” Exp Parasitol, 132(2): 116-122 (2012).
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1):1-19 (1977).
[cited by applicant]
Booher et al., “Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model”, Blood, 130(1): 1534, (2017).
[cited by applicant]
Borg et al., “1,2,4-Oxadiazole Derivatives of Phenylalnine: Potential Inhibitors of Substance P Endopeptidase,” Eur. J. Med. Chem., 28(10):801-810 (1993).
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,” Pharmaceutical Research, 12(7):945-954 (1995).
[cited by applicant]
CAS Registry No. 1557852-63-7 (2014).
[cited by applicant]
CAS Registry No. 1848907-06-1 (2016).
[cited by applicant]
CAS Registry No. 1848909-97-6 (2016).
[cited by applicant]
CAS Registry No. 1857027-85-0 (2016).
[cited by applicant]
CAS Registry No. 1868388-36-6 (2016).
[cited by applicant]
CAS Registry No. 1868393-26-3 (2016).
[cited by applicant]
CAS Registry No. 1869758-25-7 (2016).
[cited by applicant]
CAS Registry No. 1875311-16-2 (2016).
[cited by applicant]
CAS Registry No. 1878569-90-4 (2016).
[cited by applicant]
Extended European Search Report for EP Application No. 16761169.8 mailed Jul. 2, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. 16761184.7 mailed Jun. 26, 2018.
[cited by applicant]
Extended European Search Report for European Application No. 18162983.3 mailed Jun. 27, /2018.
[cited by applicant]
Graham “Clinical Trials of HIV Vaccines,” HIV Molecular Immunology Database 2000. Edited by: Korber BT, Brander C, Haynes BF, Koup R, Kuiken C, Moore JP, Walker BD, and Watkins D. Published by: Theoretical Biology and B…
[cited by applicant]
Guo et al., “Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists,” Bioorg Med Chem Letts 22(7):2572-2578 (2012).
[cited by applicant]
Harvey “Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer,” Nature, 96: 214-223 (2014).
[cited by applicant]
International Preliminary Report On Patentability for International Application No. PCT/IB2018/058526 mailed May 14, 2020.
[cited by applicant]
International Search Report and Written Opinionor International Application No. PCT/CN 2017/104485 dated Jun. 29, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2014/064279 mailed Dec. 12, 2014.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051266 mailed Jul. 8, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/IB2016/051343 mailed Jul. 28, 2016.
[cited by applicant]
International Search Report and WRITTEN OPINIONfor International Application No. PCT/IB2017/056462 dated Jan. 10, 2018.
[cited by applicant]
CAS Registry No. 1252104-30-5 (2013).
[cited by applicant]
CAS Registry No. 1356744-17-6 (2012).
[cited by applicant]
CAS Registry No. 146429-76-5 (2013).
[cited by applicant]
CAS Registry No. 1494629-78-5 (2013).
[cited by applicant]
CAS Registry No. 1496514-97-6 (2013).
[cited by applicant]
CAS Registry No. 1496518-51-4 (2013).
[cited by applicant]
CAS Registry No. 1868314-35-5 (2016).
[cited by applicant]
CAS Registry No. 1870159-31-1 (2016).
[cited by applicant]
CAS Registry No. 1875758-09-0 (2016).
[cited by applicant]
CAS Registry No. 876710-85-9 (2006).
[cited by applicant]
Brittain “Polymorphism in pharmaceutical solids,” edited by H.G Brittain, D.J.W. Grant (chapter 1) p. 1-10 and J.K. Guillory (Chapter 5) p. 183-226 (1999).
[cited by applicant]
Censi et al., “Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs,” Molecules, 20(10): 18759-18776 (2015).
[cited by applicant]
Clinical Trial NCT 02812875., “A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas,” U.S. National Library of Medicine: 7 pages (2016).
[cited by applicant]
Clinical Trial NCT02671955., “A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer,” U.S. National Library of Medicine: 9 pages (2016).
[cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 172410-37-6, 1996.
[cited by applicant]
Database Registry Chemical Abstracts, STN Accession No. 197083-27-5, 1997.
[cited by applicant]
Dempke et al., “Second-and third-generation drugs for immuno-oncology treatment—The more the better?” Eur J Cancer, 74: 55-72 (2017).
[cited by applicant]
Deng et al., “A New VISTA on combination therapy for negative checkpoint regulator blockade” Journal for Immunotherapy of Cancer, 4(86): 1-7 (2016).
[cited by applicant]
Extended European Search Report for EP Application No. 17862427.6 dated Jun. 5, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. 18863750.8 dated May 31, 2021 .
[cited by applicant]
Lee “A practical guide to pharmaceutical polymorph screening & selection,” Asian J Pharm Sci, 9(4): 163-175 (2014).
[cited by applicant]
Newman “Specialized Solid Form Screening Techniques,” Org Process Res Dev, 13(3): 457-471 (2012).
[cited by applicant]
Ozcan et al., “Oxadiazole-Isopropylamieds as Potent and Noncovalent Proteasome Inhibitors,” J. Med. Chem., 56 (10):3783-3805 (2013).
[cited by applicant]
Palazzo et al., “1,2,4-Oxadiazoles—IV. Synthesis and Pharmacological Properties of a Series of Substituted Aminoalkyl-1,2,4-Oxadiazoles,” J. Med. Chem., 351-367 (1961).
[cited by applicant]
Patwardhan et al., “Structure-Activity Relationship Studies and in Vivo Activity of Guanidine-Based Sphingosine Kinase Inhibitors: Discovery of SphK1- and SphK2-Selective Inhibitors,” J. Med. Chem., 58(4):1879-1899 (201…
[cited by applicant]
Pedoeem et al., “Programmed Death-1 Pathway in Cancer and Autoimmunity,” Clinical Immunology, 153: 145-152 (2014).
[cited by applicant]
Rabadi et al., ““The role of VISTA in the tumor microenvironment”” Journal of Cancer Metastasis and Treatment, 8 (24): 1-14 (2022).
[cited by applicant]
Rietz et al., “Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3),” J Med Chem, 64: 14757-14772 (2021).
[cited by applicant]
Sasikumar et al., “PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy,” Communications Biology, 4: 12 pages (2021).
[cited by applicant]
Shi et al., “The Role of PD-1 and PD-L1 in T-cell Immune Suppression in Patients with Hematological Malignancies,” Journal of Hematology & Oncology, 6(74): 1-6 (2013).
[cited by applicant]
Skrdla et al., “A Simple Quantitative FT-IR Approach for the Study of a Polymorphic Transformation Under Crystallization Slurry Conditions”, Journal of Pharmaceutical and Biomedical Analysis, 25(5-6): 731-739 (2001).
[cited by applicant]
Sureshbabu et al., “Synthesis of 1,2,4-oxadiazole-linked Orthogonally Urethane-Protected Dipeptide Mimetics,” Tetrahedron Letters, 49(35): 5133-5136 (2008).
[cited by applicant]
Tagliamento et al., “VISTA: A Promising Target for Cancer Immunotherapy?” ImmunoTargets and Therapy, 10: 185-200 (2021).
[cited by applicant]
Waldman “Effective Cancer Therapy Through Immunomodulation,” T Annu Rev Med, 57: 65-81 (2006).
[cited by applicant]
Wu et al., “VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses,” RSC Med Chem, 12: 1672-1679 (2021).
[cited by applicant]